Does Size Matter? These Two Small-Cap Cannabis Stocks Are Masters Of Cash Flow And Credit Management
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 12 2024
0mins
Source: Benzinga
Financial Performance of C21 Investments and Vext Science: Both companies have shown strong financial performance with notable cash flow margins, outperforming larger cannabis firms despite their smaller market caps. C21 Investments has an LFCFM of 12.3%, while Vext Science has 4.1%, indicating efficient revenue conversion into cash.
Credit Rankings and Market Comparison: C21 Investments and Vext Science rank highly in credit stability within the small-cap cannabis sector, with C21 at #2 and Vext at #1. Their ability to manage debt is reflected in their low total liabilities to market cap ratios, contrasting sharply with the significantly higher prices of larger competitors like Tilray and Curaleaf.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLRY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLRY is 9.57 USD with a low forecast of 8.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 7.620
Low
8.50
Averages
9.57
High
10.00
Current: 7.620
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tilray Brands Rebrands Italian Medical Cannabis Unit to Expand European Footprint
- Market Restructuring: Tilray Medical Italia replaces FL Group, marking a strategic reorganization in Italy's medical cannabis sector aimed at unifying compliance platforms across key European markets and enhancing brand influence.
- Product Diversification: The new entity will offer a range of medicines approved by Italy's health authorities, including high-THC flowers and THC-CBD oil, catering to diverse medical needs while ensuring compliance with strict EU-GMP standards.
- Partnership Enhancement: Collaboration with Molteni Farmaceutici will bolster Tilray's distribution capabilities in Italy, increasing physician engagement and ensuring responsible prescribing through hospitals, doctors, and pharmacies.
- Strategic Importance: Tilray emphasizes the significance of the Italian market, committing to building a leading medical cannabis platform in Europe while supporting compliance operations in over 20 countries and promoting evidence-based therapeutic solutions.
Continue Reading
SweetWater Brewing Launches Big Trip Double IPA with 9% ABV to Strengthen Market Position
- New Product Launch: SweetWater Brewing introduces Big Trip Double IPA with a 9% ABV, aiming to capitalize on the success of its popular Daytrip IPA to further attract craft beer enthusiasts and casual drinkers.
- Market Trend Alignment: With Double IPAs trending as the second most popular craft style in the Southeast, SweetWater's launch of Big Trip strengthens its competitive position in the high-ABV beer market.
- Sales Strategy Optimization: Big Trip will be available in 19.2 oz and 6-pack 12 oz formats, aligning with the packaging preferences that account for 80% of sales for high-ABV brews in the Southeast, thereby enhancing sales performance.
- Brand Expansion Plan: SweetWater aims to enrich its product portfolio through the launch of Big Trip, solidifying its leadership position in the Southeast craft beer market while supporting its environmental initiatives.
Continue Reading